Synergism of antihypertensives and cholinesterase inhibitors in Alzheimer's disease

Alzheimer's and Dementia: Translational Research and Clinical Interventions

Volumn 4, Issue , 2018, Pages 542-555

  Hu, Ziheng ^a   Wang, Lirong ^a   Ma, Shifan ^a   Kirisci, Levent ^a   Feng, Zhiwei ^a   Xue, Ying ^a,b   Klunk, William E ^c   Kamboh, M Ilyas ^a   Sweet, Robert A ^c   Becker, James ^c   Lv, Qianzhou ^b   Lopez, Oscar L ^c   Xie, Xiang Qun ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b FUDAN UNIVERSITY   (China)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Antihypertensive medications; Cholinesterase inhibitors; Clinical data mining; Cognitive decline; Combination therapy; Systems pharmacology

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN E4; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLINESTERASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; LOSARTAN; PLACEBO; VASODILATOR AGENT;

AGED; ALZHEIMER DISEASE; ARTICLE; BLINDNESS; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; FEMALE; HETEROZYGOTE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 85055490106     PISSN: None     EISSN: 23528737     Source Type: Journal    
DOI: 10.1016/j.trci.2018.09.001     Document Type: Article

References (102)

1. Drugs for Alzheimer's disease: Best avoided. No therapeutic advantage. Prescrire Int, 21, 2012, 150.
2. Schmitt, B., Bernhardt, T., Moeller, H.-J., Heuser, I., Frölich, L., Combination therapy in Alzheimer's disease. CNS Drugs 18 (2004), 827–844.
3. Sakurai, H., Hanyu, H., Kanetaka, H., Sato, T., Shimizu, S., Hirao, K., et al. Prevalence of coexisting diseases in patients with Alzheimer's disease. Geriatr Gerontol Int 10 (2010), 216–217.
4. Zlokovic, B.V., Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 12 (2011), 723–738.
5. Qiu, C., Winblad, B., Fratiglioni, L., The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 4 (2005), 487–499.
6. Gottesman, R.F., Schneider, A.L., Albert, M., Alonso, A., Bandeen-Roche, K., Coker, L., et al. Midlife hypertension and 20-year cognitive change: The atherosclerosis risk in communities neurocognitive study. JAMA Neurol 71 (2014), 1218–1227.
7. Ruitenberg, A., Skoog, I., Ott, A., Aevarsson, O., Witteman, J.C., Lernfelt, B., et al. Blood pressure and risk of dementia: Results from the Rotterdam study and the Gothenburg H-70 Study. Dement Geriatr Cogn Disord 12 (2001), 33–39.
8. Verghese, J., Lipton, R.B., Hall, C.B., Kuslansky, G., Katz, M.J., Low blood pressure and the risk of dementia in very old individuals. Neurology 61 (2003), 1667–1672.
9. Kuller, L.H., Lopez, O.L., Newman, A., Beauchamp, N.J., Burke, G., Dulberg, C., et al. Risk factors for dementia in the Cardiovascular Health Cognition Study. Neuroepidemiology 22 (2003), 13–22.
10. Petitti, D.B., Crooks, V.C., Buckwalter, J.G., Chiu, V., Blood pressure levels before dementia. Arch Neurol, 62, 2005, 112.
11. Skoog, I., Nilsson, L., Persson, G., Lernfelt, B., Landahl, S., Palmertz, B., et al. 15-year longitudinal study of blood pressure and dementia. Lancet 347 (1996), 1141–1145.
12. Qiu, C., von Strauss, E., Fastbom, J., Winblad, B., Fratiglioni, L., Low blood pressure and risk of dementia in the Kungsholmen project: A 6-year follow-up study. Arch Neurol 60 (2003), 223–228.
13. Gelber, R.P., Ross, G.W., Petrovitch, H., Masaki, K.H., Launer, L.J., White, L.R., Antihypertensive medication use and risk of cognitive impairment: The Honolulu-Asia Aging Study. Neurology 81 (2013), 888–895.
14. Soto, M.E., Abellan van Kan, G., Nourhashemi, F., Gillette-Guyonnet, S., Cesari, M., Cantet, C., et al. Angiotensin-converting enzyme inhibitors and Alzheimer's disease progression in older adults: Results from the réseau sur la maladie d'Alzheimer français cohort. J Am Geriatr Soc 61 (2013), 1482–1488.
15. Forette, F., Seux, M.-L., Staessen, J.A., Thijs, L., Babarskiene, M.-R., Babeanu, S., et al. The prevention of dementia with antihypertensive treatment: New evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 162 (2002), 2046–2052.
16. Peters, R., Beckett, N., Forette, F., Tuomilehto, J., Clarke, R., Ritchie, C., et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): A double-blind, placebo controlled trial. Lancet Neurol 7 (2008), 683–689.
17. Hajjar, I., Catoe, H., Sixta, S., Boland, R., Johnson, D., Hirth, V., et al. Cross-sectional and longitudinal association between antihypertensive medications and cognitive impairment in an elderly population. J Gerontol A Biol Sci Med Sci 60 (2005), 67–73.
18. Guo, Z., Fratiglioni, L., Zhu, L., Fastbom, J., Winblad, B., Viitanen, M., Occurrence and progression of dementia in a community population aged 75 years and older: Relationship of antihypertensive medication use. Arch Neurol 56 (1999), 991–996.
19. Wang, L., Xie, X.-Q., Computational target fishing: What should chemogenomics researchers expect for the future of in silico drug design and discovery?. Future Med Chem 6 (2014), 247–249.
20. Xie, X.-Q., Wang, L., Liu, H., Ouyang, Q., Fang, C., Su, W., Chemogenomics knowledgebased polypharmacology analyses of drug abuse related G-protein coupled receptors and their ligands. Front Pharmacol, 5, 2014.
21. Wang, L., Ma, C., Wipf, P., Liu, H., Su, W., Xie, X.-Q., TargetHunter: An In Silico Target Identification Tool for predicting therapeutic potential of small organic molecules based on chemogenomic database. AAPS J 15 (2013), 395–406.
22. Liu, H., Wang, L., Lv, M., Pei, R., Li, P., Pei, Z., et al. AlzPlatform: An Alzheimer's disease domain-specific chemogenomics knowledgebase for polypharmacology and target identification research. J Chem Inf Model 54 (2014), 1050–1060.
23. Zhang, H., Ma, S., Feng, Z., Wang, D., Li, C., Cao, Y., et al. Cardiovascular Disease Chemogenomics Knowledgebase-guided Target Identification and Drug Synergy Mechanism Study of an herbal formula. Sci Rep, 6, 2016, 33963.
24. Lopez, O.L., Becker, J.T., Wahed, A.S., Saxton, J., Sweet, R.A., Wolk, D.A., et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 80 (2009), 600–607.
25. Kamboh, M., The relationship of APOE polymorphism and cholesterol levels in normoglycemic and diabetic subjects in a biethnic population from the San Luis Valley, Colorado. Atherosclerosis 112 (1995), 145–159.
26. Chiou, S.-Y., Lai, G.-W., Tsai, Y.-H., Lin, L.-Y., Lin, G., QSAR for acetylcholinesterase and butyrylcholinesterase inhibition by cardiovascular drugs and benzodiazepines. Med Chem Res 14 (2005), 297–308.
27. Moore, P.F., The effects of diazoxide and benzothiadiazine diuretics upon phosphodiesterase. Ann N Y Acad Sci 150 (1968), 256–260.
28. Schupp, M., Lee, L.D., Frost, N., Umbreen, S., Schmidt, B., Unger, T., et al. Regulation of peroxisome proliferator–activated receptor γ activity by losartan metabolites. Hypertension 47 (2006), 586–589.
29. Group, S.R., A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373 (2015), 2103–2116.
30. Kherada, N., Heimowitz, T., Rosendorff, C., Antihypertensive therapies and cognitive function: A review. Curr Hypertens Rep, 17, 2015, 79.
31. Starr, J.M., Whalley, L.J., Deary, I.J., The effects of antihypertensive treatment on cognitive function: Results from the HOPE study. J Am Geriatr Soc 44 (1996), 411–415.
32. Collaborative, P., Neal, B., MacMahon, S., Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 163 (2003), 1069–1075.
33. Yagi, S., Akaike, M., Aihara, K-i, Iwase, T., Yoshida, S., Sumitomo-Ueda, Y., et al. High plasma aldosterone concentration is a novel risk factor of cognitive impairment in patients with hypertension. Hypertens Res 34 (2010), 74–78.
34. Trompet, S., Westendorp, R.G., Kamper, A.M., de Craen, A.J., Use of calcium antagonists and cognitive decline in old age: The Leiden 85-Plus Study. Neurobiol Aging 29 (2008), 306–308.
35. de Oliveira, F.F., Chen, E.S., Smith, M.C., Bertolucci, P.H.F., Associations of blood pressure with functional and cognitive changes in patients with Alzheimer's disease. Dement Geriatr Cogn Disord 41 (2016), 314–323.
36. Fogari, R., Mugellini, A., Zoppi, A., Lazzari, P., Destro, M., Rinaldi, A., et al. Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. J Hum Hypertens 20 (2005), 177–185.
37. Douiri, A., McKevitt, C., Emmett, E.S., Rudd, A.G., Wolfe, C.D.A., Long-term effects of secondary prevention on cognitive function in stroke patients. Circulation 128 (2013), 1341–1348.
38. Salloway, S., Ferris, S., Kluger, A., Goldman, R., Griesing, T., Kumar, D., et al. Efficacy of donepezil in mild cognitive impairment: A randomized placebo-controlled trial. Neurology 63 (2004), 651–657.
39. Koontz, J., Baskys, A., Effects of galantamine on working memory and global functioning in patients with mild cognitive impairment: A double-blind placebo-controlled study. Am J Alzheimers Dis Other Demen 20 (2005), 295–302.
40. Feldman, H., Gauthier, S., Hecker, J., Vellas, B., Subbiah, P., Whalen, E., A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 57 (2001), 613–620.
41. Courtney, C., Farrell, D., Gray, R., Hills, R., Lynch, L., Sellwood, E., et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): Randomised double-blind trial. Lancet 363 (2004), 2105–2115.
42. Lopez, O.L., Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry 72 (2002), 310–314.
43. Raschetti, R., Maggini, M., Sorrentino, G.C., Martini, N., Caffari, B., Vanacore, N., A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease. Eur J Clin Pharmacol 61 (2005), 361–368.
44. Miranda, L.F., Gomes, K.B., Silveira, J.N., Pianetti, G.A., Byrro, R., Peles, P.R., et al. Predictive factors of clinical response to cholinesterase inhibitors in mild and moderate Alzheimer's disease and mixed dementia: A one-year naturalistic study. J Alzheimers Dis 45 (2015), 609–620.
45. Khachaturian, A.S., Zandi, P.P., Lyketsos, C.G., Hayden, K.M., Skoog, I., Norton, M.C., et al. Antihypertensive medication use and incident Alzheimer disease: The Cache County Study. Arch Neurol 63 (2006), 686–692.
46. Yasar, S., Xia, J., Yao, W., Furberg, C.D., Xue, Q.L., Mercado, C.I., et al. Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study. Neurology 81 (2013), 896–903.
47. Nelson, L., Tabet, N., Richardson, C., Gard, P., Antihypertensives, angiotensin, glucose and Alzheimer's disease. Expert Rev Neurother 13 (2013), 477–482.
48. Rogerson, F., Determinants of spironolactone binding specificity in the mineralocorticoid receptor. J Mol Endocrinol 31 (2003), 573–582.
49. Puscas, I., Coltau, M., Baican, M., Domuta, G., Hecht, A., Vasodilatory effect of diuretics is dependent on inhibition of vascular smooth muscle carbonic anhydrase by a direct mechanism of action. Drugs Exp Clin Res 25 (1999), 271–279.
50. Chen, X., TTD: Therapeutic target database. Nucleic Acids Res 30 (2002), 412–415.
51. Fossati, S., Giannoni, P., Solesio, M.E., Cocklin, S.L., Cabrera, E., Ghiso, J., et al. The carbonic anhydrase inhibitor methazolamide prevents amyloid beta-induced mitochondrial dysfunction and caspase activation protecting neuronal and glial cells in vitro and in the mouse brain. Neurobiol Dis 86 (2016), 29–40.
52. Fritze, J., Walden, J., Clinical findings with nimodipine in dementia: Test of the calcium hypothesis. J Neural Transm Suppl 46 (1995), 439–453.
53. Anekonda, T.S., Quinn, J.F., Calcium channel blocking as a therapeutic strategy for Alzheimer's disease: The case for isradipine. Biochim Biophys Acta 1812 (2011), 1584–1590.
54. Birks, J., López-Arrieta, J., Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev, 2002, CD000147 John Wiley & Sons, Ltd.
55. Nimmrich, V., Eckert, A., Calcium channel blockers and dementia. Br J Pharmacol 169 (2013), 1203–1210.
56. Willis, M., Kaufmann, W.A., Wietzorrek, G., Hutter-Paier, B., Moosmang, S., Humpel, C., et al. L-type calcium channel CaV 1.2 in transgenic mice overexpressing human AβPP751 with the London (V717I) and Swedish (K670M/N671L) mutations. J Alzheimers Dis 20 (2010), 1167–1180.
57. Samer, C.F., Daali, Y., Wagner, M., Hopfgartner, G., Eap, C.B., Rebsamen, M.C., et al. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. Br J Pharmacol 160 (2010), 907–918.
58. Abadir, P.M., Foster, D.B., Crow, M., Cooke, C.A., Rucker, J.J., Jain, A., et al. Identification and characterization of a functional mitochondrial angiotensin system. Proc Natl Acad Sci U S A 108 (2011), 14849–14854.
59. Ashby, E.L., Kehoe, P.G., Current status of renin–aldosterone angiotensin system-targeting anti-hypertensive drugs as therapeutic options for Alzheimer's disease. Expert Opin Investig Drugs 22 (2013), 1229–1242.
60. Kehoe, P.G., Miners, S., Love, S., Angiotensins in Alzheimer's disease–friend or foe?. Trends Neurosci 32 (2009), 619–628.
61. Kehoe, P.G., Davies, N.M., Martin, R.M., Ben-Shlomo, Y., Associations of angiotensin targeting antihypertensive drugs with mortality and hospitalization in primary care patients with dementia. J Alzheimers Dis 33 (2013), 999–1008.
62. Carson, J.A., Turner, A.J., β-Amyloid catabolism: Roles for neprilysin (NEP) and other metallopeptidases?. J Neurochem 81 (2002), 1–8.
63. Fyhrquist, F., Saijonmaa, O., Renin-angiotensin system revisited. J Intern Med 264 (2008), 224–236.
64. Wright, J.W., Harding, J.W., Brain renin-angiotensin—a new look at an old system. Prog Neurobiol 95 (2011), 49–67.
65. Stragier, B., De Bundel, D., Sarre, S., Smolders, I., Vauquelin, G., Dupont, A., et al. Involvement of insulin-regulated aminopeptidase in the effects of the renin–angiotensin fragment angiotensin IV: A review. Heart Fail Rev 13 (2007), 321–337.
66. Vanderheyden, P.M.L., From angiotensin IV binding site to AT4 receptor. Mol Cell Endocrinol 302 (2009), 159–166.
67. Hua, F., Zhou, J., Liu, J., Zhu, C., Cui, B., Lin, H., et al. Glycogen synthase kinase-3β negatively regulates TGF-β1 and angiotensin II-mediated cellular activity through interaction with Smad3. Eur J Pharmacol 644 (2010), 17–23.
68. Pohanka, M., Acetylcholinesterase inhibitors: A patent review (2008—present). Expert Opin Ther Pat 22 (2012), 871–886.
69. Greig, N.H., Utsuki, T., Yu, Q.-S., Zhu, X., Holloway, H.W., Perry, T., et al. A new therapeutic target in Alzheimer's disease treatment: Attention to butyrylcholinesterase. Curr Med Res Opin 17 (2001), 159–165.
70. Riederer, P., Danielczyk, W., Grünblatt, E., Monoamine oxidase-B inhibition in Alzheimer's disease. Neurotoxicology 25 (2004), 271–277.
71. Andreyev, A.Y., Kushnareva, Y.E., Starkov, A., Mitochondrial metabolism of reactive oxygen species. Biochemistry 70 (2005), 200–214.
72. Huang, W.J., Zhang, X., Chen, W.W., Role of oxidative stress in Alzheimer's disease. Biomed Rep 4 (2016), 519–522.
73. Weyler, W., Hsu, Y.-P.P., Breakafield, X.O., Biochemistry and genetics of monoamine oxidase. Pharmacol Ther 47 (1990), 391–417.
74. Ciccone, C.D., Free-radical toxicity and antioxidant medications in Parkinson's disease. Phys Ther 78 (1998), 313–319.
75. Law, A., Gauthier, S., Quirion, R., Say NO to Alzheimer's disease: The putative links between nitric oxide and dementia of the Alzheimer's type. Brain Res Rev 35 (2001), 73–96.
76. Eliasson, M.J., Huang, Z., Ferrante, R.J., Sasamata, M., Molliver, M.E., Snyder, S.H., et al. Neuronal nitric oxide synthase activation and peroxynitrite formation in ischemic stroke linked to neural damage. J Neurosci 19 (1999), 5910–5918.
77. Segarra, V., Crespo, M.I., Pujol, F., Beleta, J., Doménech, T., Miralpeix, M., et al. Phosphodiesterase inhibitory properties of losartan. Design and synthesis of new lead compounds. Bioorg Med Chem Lett 8 (1998), 505–510.
78. Impey, S., Mark, M., Villacres, E.C., Poser, S., Chavkin, C., Storm, D.R., Induction of CRE-mediated gene expression by stimuli that generate long-lasting LTP in area CA1 of the hippocampus. Neuron 16 (1996), 973–982.
79. García-Osta, A., Cuadrado-Tejedor, M., García-Barroso, C., Oyarźbal, J., Franco, R., Phosphodiesterases as therapeutic targets for Alzheimer's disease. ACS Chem Neurosci 3 (2012), 832–844.
80. Tully, T., Regulation of gene expression and its role in long-term memory and synaptic plasticity. Proc Natl Acad Sci U S A 94 (1997), 4239–4241.
81. Munoz, L., Ammit, A.J., Targeting p38 MAPK pathway for the treatment of Alzheimer's disease. Neuropharmacology 58 (2010), 561–568.
82. Schieven, G.L., The biology of p38 kinase: A central role in inflammation. Curr Top Med Chem 5 (2005), 921–928.
83. Bodles, A.M., Barger, S.W., Secreted β-amyloid precursor protein activates microglia via JNK and p38-MAPK. Neurobiol Aging 26 (2005), 9–16.
84. Bhat, N.R., Feinstein, D.L., Shen, Q., Bhat, A.N., p38 MAPK-mediated transcriptional activation of inducible nitric-oxide synthase in glial cells. Roles of nuclear factors, nuclear factor kappa B, cAMP response element-binding protein, CCAAT/enhancer-binding protein-beta, and activating transcription factor-2. J Biol Chem 277 (2002), 29584–29592.
85. Sheng, J.G., Jones, R.A., Zhou, X.Q., McGinness, J.M., Van Eldik, L.J., Mrak, R.E., et al. Interleukin-1 promotion of MAPK-p38 overexpression in experimental animals and in Alzheimer's disease: Potential significance for tau protein phosphorylation. Neurochem Int 39 (2001), 341–348.
86. Minghetti, L., Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol 63 (2004), 901–910.
87. Aisen, P.S., Evaluation of selective COX-2 inhibitors for the treatment of Alzheimer's disease. J Pain Symptom Manage 23 (2002), S35–S40.
88. Aisen, P.S., Schafer, K.A., Grundman, M., Pfeiffer, E., Sano, M., Davis, K.L., et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: A randomized controlled trial. JAMA 289 (2003), 2819–2826.
89. Mash, D.C., Flynn, D.D., Potter, L.T., Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science 228 (1985), 1115–1118.
90. Ni, Y., Zhao, X., Bao, G., Zou, L., Teng, L., Wang, Z., et al. Activation of β2-adrenergic receptor stimulates γ-secretase activity and accelerates amyloid plaque formation. Nat Med 12 (2006), 1390–1396.
91. Gong, C.-X., Iqbal, K., Hyperphosphorylation of microtubule-associated protein tau: A promising therapeutic target for Alzheimer disease. Curr Med Chem 15 (2008), 2321–2328.
92. Lau, L., Schachter, J.B., Seymour, P.A., Sanner, M.A., Tau protein phosphorylation as a therapeutic target in Alzheimer's disease. Curr Top Med Chem 2 (2002), 395–415.
93. Weingarten, M.D., Lockwood, A.H., Hwo, S.-Y., Kirschner, M.W., A protein factor essential for microtubule assembly. Proc Natl Acad Sci U S A 72 (1975), 1858–1862.
94. Alonso, A.D.C., Zaidi, T., Grundke-Iqbal, I., Iqbal, K., Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc Natl Acad Sci U S A 91 (1994), 5562–5566.
95. Kersten, S., Desvergne, B., Wahli, W., Roles of PPARs in health and disease. Nature 405 (2000), 421–424.
96. Spiegelman, B., PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor. Diabetes 47 (1998), 507–514.
97. Landreth, G., Jiang, Q., Mandrekar, S., Heneka, M., PPARγ agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics 5 (2008), 481–489.
98. Waldstein, S.R., Giggey, P.P., Thayer, J.F., Zonderman, A.B., Nonlinear relations of blood pressure to cognitive function: The Baltimore Longitudinal Study of Aging. Hypertension 45 (2005), 374–379.
99. Reinprecht, F., Elmståhl, S., Janzon, L., André-Petersson, L., Hypertension and changes of cognitive function in 81-year-old men: A 13-year follow-up of the population study “Men born in 1914” Sweden. J Hypertens 21 (2003), 57–66.
100. Guo, Z., Fratiglioni, L., Winblad, B., Viitanen, M., Blood pressure and performance on the Mini-Mental State Examination in the very old: Cross-sectional and longitudinal data from the Kungsholmen Project. Am J Epidemiol 145 (1997), 1106–1113.
101. Bohannon, A.D., Fillenbaum, G.G., Pieper, C.F., Hanlon, J.T., Blazer, D.G., Relationship of race/ethnicity and blood pressure to change in cognitive function. J Am Geriatr Soc 50 (2002), 424–429.
102. de Oliveira, F.F., Bertolucci, P.H.F., Chen, E.S., Smith, M.C., Brain-penetrating angiotensin-converting enzyme inhibitors and cognitive change in patients with dementia due to Alzheimer's disease. J Alzheimers Dis 42 (2014), S321–S324.